Brief reportA randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression
Introduction
Treatment-resistant depression continues to represent a major challenge for clinicians: only 50 to 60% of patients respond to the first antidepressant given (Kroenke et al., 2001). Switching to a different monotherapy antidepressant medication is the preferred option for many patients and clinicians. The possible advantages of switching to a different monotherapy, as compared with adding a second agent (i.e., augmenting or combining), include reduced medication costs, fewer drug interactions, better adherence, and less patient burden over time (Marangell, 2001). In addition, switching to a different antidepressant may be quite appealing to patients, especially when the alternative drug has a more acceptable side effect profile (Fava, 2000, Fava and Rush, 2006).
There are two major types of switching strategies studied in literature: within-class switch and across-class switch. Recently, level 2 of the STAR*D trial compared switching patients with no remission of symptoms from citalopram to bupropion, sertraline or venlafaxine: no differences in efficacy or tolerability emerged between the three treatment groups, with remission rates across treatments of approximately 25% (Rush et al., 2006). The results of a recent meta-analysis conducted by Papakostas et al. suggest a modest yet statistically significant advantage in remission rates when switching patients with SSRI-resistant depression to a non-SSRI rather than an SSRI antidepressant (Papakostas et al., 2008): it is, however, a limitation that only three non-SSRIs (venlafaxine, mirtazapine, and bupropion) were included in the meta-analysis and that most of the studies involved venlafaxine, with the advantage noted being evident regardless of whether or not the two comparisons that utilized mirtazapine and bupropion were included.
Respect to switching strategies from SSRIs to duloxetine, data are limited: an open-label trial conducted on a sample of 40 elderly subjects who have not responded to escitalopram, suggest that duloxetine at doses up to 120 mg/day is a potentially effective and well-tolerated treatment (Karp et al., 2008). In addition, the results of a multicentre trial comparing two different switching strategies from SSRIs to duloxetine (direct switch or start-taper switch) in patients with major depression suggest significant improvements in both emotional and painful physical symptoms of depression regardless of which of the switch methods was used (Perahia et al., 2006).
On the basis of these findings, we hypothesize that, in patients unresponsive to SSRIs, the administration of an antidepressant with a different mechanism of action may be an effective switching strategy. The aim of this study is to compare the efficacy of two different dual-action compounds, duloxetine and bupropione, in patients with major depression unresponsive to SSRIs.
Section snippets
Patients
Patients were recruited from referrals to the Mood and Anxiety Disorders Unit, Department of Neuroscience, University of Turin, Italy. This is a tertiary referral center mainly for patients from the Piedmont and Aosta Valley regions of Italy, located in the University General Hospital. Patients are referred by general practitioners, psychiatrists or psychologists due to an anxiety or mood disorder diagnosis (or hypothesized diagnosis), although a few are self-referred (e.g. via information
Results
A total of 49 participants were randomly assigned to duloxetine 120 mg (n = 27) or bupropion 300 mg (n = 22). The SSRI treatments taken by randomized patients before the inclusion in the study are showed in Table 1.
The dropout rate was 7.4% (n = 2) in the duloxetine group, and 4.5% (n = 1) in the bupropion group (difference not statistically significant). In the group of patients treated with duloxetine, the dropouts were due to the fact that patients didn't take any medication (n = 1) or stopped
Discussion
This study addresses the pragmatic question of the clinical utility of switching strategy in case of inadequate response to an antidepressant treatment. The majority of previous studies on this topic have considered patients unresponsive to a single SSRI trial, evaluating the efficacy of within-class and across-class switching (Ruhè et al., 2006, Thase, 2004) and suggesting a modest advantage when switching to a non-SSRI rather than another SSRI antidepressant (Papakostas et al., 2008).
Role of funding source
None.
Conflict of interest
G. Rosso: None declared.
S. Rigardetto: None declared.
F. Bogetto: None declared.
G. Maina: None declared.
References (20)
- et al.
Are antidepressant drugs that combine serotoninergic and noradrenergic mechanisms of action more effective than the selective serotonine reuptake inhibitors in treating Major Depressive Disorder? A meta-analysis of studies of newer agents
Biol. Psychiatry
(2007) - et al.
Treatment of SSRI-resistant depression: meta-analysis comparing within- versus across-class switches
Biol. Psychiatry
(2008) - et al.
Duloxetine in the treatment of major depressive disorder: a placebo and paroxetine controlled trial
Eur. Psychiatry
(2006) DSM-IV-TR Diagnostic and Statistic Manual of Mental Health Disorders Text Revision, ed. 4
(2000)Management of nonresponse and intolerance: switching strategies
J. Clin. Psychiatry
(2000)- et al.
Current status of augmentation and combination treatments of major depressive disorder: a literature review and a proposal for a novel approach to improve practice
Psychother. Psychosom.
(2006) - et al.
Structured Clinical Interview for DSM-IV Axis I Disorders
(1997) Development of a rating scale for primary depressive illness
Br. J. Soc. Clin. Psychol.
(1967)- et al.
A brief mental health outcome scale: reliability and validity of the Global Assessment of Functioning (GAF)
Br. J. Psychiatry
(1976)
Cited by (21)
Clinical and epidemiological predictors of treatment-resistant depression
2022, Managing Treatment-Resistant Depression: Road to Novel TherapeuticsDuloxetine usage in depression
2021, The Neuroscience of Depression: Features, Diagnosis, and TreatmentSocio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review
2016, Psychiatry ResearchCitation Excerpt :Therefore, among comorbidities, if anxiety disorders and personality disorders may influence both response and remission, it was not the case for axis III comorbidities. A lot of psychosocial and environment variables were investigated, but no one was associated with non-response: employment (Souery et al., 2007; Fang et al., 2010; Di Nasso et al., 2011; Rosso et al., 2012), lower educational status (Souery et al., 2007; Karp et al., 2008; Fang et al., 2010; Di Nasso et al., 2011; Rosso et al., 2012), being or not being married (Agid and Lerer, 2003; Souery et al., 2007; Karp et al., 2008; Fang et al., 2010; Di Nasso et al., 2011; Rosso et al., 2012), and adverse life events, in particular recent adverse events (Agid and Lerer, 2003). On the contrary, marital status seemed to be a protective factor for non-remission (Perlis et al., 2003) and a trend of association between divorced/widowed status and rate of remission was found (Di Nasso et al., 2011).
Unsatisfactory response: definition and involvement
2016, EncephaleSocio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study
2016, Journal of Affective DisordersDuloxetine usage in depression
2021, The Neuroscience of Depression, 1st Edition: Volume 1-2